United States has announced steep tariffs of up to 100% on patented drugs, sparing generics and biosimilars. This move is expected to hit Indian pharmaceutical companies, especially those with strong exposure to specialty medicines.
Sun Pharma, India’s largest drugmaker, faces the biggest risk as nearly $1 billion of its sales come from the US. Analysts at Nomura estimate a 5% earnings impact if the company absorbs the costs, while Jefferies expects a mid-single-digit hit to earnings per share. Contract manufacturers like Sai Lifesciences may also feel some pressure, though their exposure is relatively modest.
The US government has justified the tariffs citing national security concerns, pointing out that more than half of patented drugs and 85% of active pharmaceutical ingredients are manufactured offshore. However, exemptions have been granted for generics, biosimilars, orphan drugs, fertility treatments, and advanced therapies like cell and gene treatments.
Indian pharma stocks reacted quickly, with Sun Pharma, Piramal Pharma, and IPCA Labs falling up to 2% in early trade. While the short-term impact looks challenging, India’s cost advantage 30–40% cheaper than US and European manufacturing may help companies stay competitive in the long run.
For investors, generic-focused firms remain safe bets, while Sun Pharma and other specialty players may need to adjust pricing strategies to protect margins.
